Journal
MOLECULAR CANCER THERAPEUTICS
Volume 15, Issue 8, Pages 1792-1798Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-16-0050
Keywords
-
Categories
Funding
- Deutsche Forschungsgemeinschaft [SFB824/C9, SCHN 959/2-1]
- Deutsche Krebshilfe [110908]
- Else-Kroner-Fresenius-Stiftung [2016_A43]
- Wilhelm-Sander-Stiftung [2016.004.1]
Ask authors/readers for more resources
Current data suggest that MYC is an important signaling hub and driver in pancreatic ductal adenocarcinoma (PDAC), a tumor entity with a strikingly poor prognosis. No targeted therapies with a meaningful clinical impact were successfully developed against PDAC so far. This points to the need to establish novel concepts targeting the relevant drivers of PDAC, like KRAS or MYC. Here, we discuss recent developments of direct or indirect MYC inhibitors and their potential mode of action in PDAC. (C)2016 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
